Integrilin eptifibatide Injection: Marketed to treat unstable angina and non-Q-wave myocardial infarction and as an adjunct to coronary angioplasty

Additional analysis of CORR's and partner Schering-Plough Corp.'s Phase III PURSUIT study showed that Integrilin reduced myocardial infarction over 30 days compared to placebo in acute coronary syndrome patients. Integrilin also reduced the extent of injury to the heart muscle.

In patients undergoing catheterization or a coronary procedure who were transferred between hospitals, Integrilin reduced the combined incidence of death or heart attack over 30 days to 17.9 percent from 23.4 percent. ...